Changes in lipid profile of patients referred to a cardiac rehabilitation program

European Journal of Preventive Cardiology

Volumn 15, Issue 4, 2008, Pages 467-472

  Sarrafzadegan, Nizal ^a   Rabiei, Katayoun ^b   Kabir, Ali ^c   Asgary, Seddighe ^d   Tavassoli, Aliakbar ^f   Khosravi, Alireza ^e   Chalian, Hamid ^c  

^a WHO Collaborating Center   (Iran)

^b Rehabilitation Department   (Iran)

^c Nikan Health Researchers Institute   (Iran)

^d Basic Research Department   (Iran)

^e ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f UNIVERSITY OF ISFAHAN   (Iran)

Author keywords

cardiac rehabilitation; coronary disease; drug effect; exercise; lipids; smoking

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTERAMIN; CLOFIBRATE; ESTROGEN; FLUINDOSTATIN; GEMFIBROZIL; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PROGESTERONE; SIMVASTATIN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VALPROIC ACID;

ANTHROPOMETRY; ARTICLE; BLOOD; CORONARY ARTERY DISEASE; FEMALE; HUMAN; MALE; MIDDLE AGED; ADULT; CHOLESTEROL BLOOD LEVEL; DESCRIPTIVE RESEARCH; DIASTOLIC BLOOD PRESSURE; FUNCTIONAL STATUS; GARLIC; HEART REHABILITATION; IRAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PATIENT REFERRAL; PRIORITY JOURNAL; SOCIAL PSYCHOLOGY; TRIACYLGLYCEROL BLOOD LEVEL;

ANTHROPOMETRY; ANTILIPEMIC AGENTS; CHOLESTEROL; CORONARY DISEASE; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 55249110859     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e328300271f     Document Type: Article

References (36)

1. Iranian Ministry of Health and Medical Education: a national survey on health and diseases in Iran. Report; 2000.
2. World Health Organization. Technical report series 894. Obesity, preventing and managing the global epidemic. Report of a WHO consultation. Geneva' World Health Organization; 2000.
3. Ghassemi H, Harrison G, Mohammad K. An accelerated nutrition transition in Iran. Public Health Nutr 2002; 5: 149–155.
4. Jalali BA, Rafie M, Mozaffari H. Lipoprotein (A) as a strong risk factor for coronary artery disease in Iranian population. Med J Islamic Acad Sci 2000; 13: 5–9.
5. Wierzbicki AS. Lipid-altering therapies and the progression of atherosclerotic disease. Cardiovasc Intervent Radiol 2007; 30: 155–160.
6. Nadar S, Lim HS, Beevers DG, Lip GY. Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study. J Hum Hypertens 2002; 16: 815–817.
7. Wenger N, Hellerstein HK, Blackburn H, Castranova SJ. Uncomplicated myocardial infarction: current physician practice in patient management. JAMA 1973; 224: 511–514.
8. Hellerstein HK. Exercise therapy in coronary disease. Bull N Y Acad Med 1968; 44: 1028–1047.
9. Mosca L, Manson JE, Sutherland SE, Langer R, Manolio T, Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96: 2468–2482.
10. Wenger N, Froelicher E, Smith L. Cardiac rehabilitation as secondary prevention. Clinical practice guideline 96–0673 1995; Rockville: US, Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, and National Heart, Lung, and Blood Institute.
11. Carhart R, Ades P. Gender differences in cardiac rehabilitation. Cardiol Clin 1998; 16: 37–43.
12. Taylor RS, Unal B, Critchley JA, Capewell S. Mortality reductions in patients receiving exercise-based cardiac rehabilitation: how much can be attributed to cardiovascular risk factor improvements? Eur J Cardiovasc Prev Rehabil 2006; 13: 369–374.
13. Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, et al Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004; 116: 682–692.
14. Ades PA. Cardiac rehabilitation and secondary prevention of coronary heart disease. N Engl J Med 2001; 345: 892–902.
15. Lavie CJ, Milani RV. Factors predicting improvements in lipid values following cardiac rehabilitation and exercise training. Arch Intern Med 1993; 153: 982–988.
16. Baardman T, Fioretti P, van Tol A, Erdman RA, van Meurs-van Woezik H, Kazemier M. Changes in plasma lipoproteins after cardiac rehabilitation in patients not on lipid-lowering drugs. Eur Heart J 1990; 11: 722–729.
17. Sanderson BK, Mirza S, Fry R, Allison JJ, Bittner V. Secondary prevention outcomes among black and white cardiac rehabilitation patients. Am Heart J 2007; 153: 980–986.
18. Harris T, Cook EF, Garrison R, Higgins M, Kannel W, Goldman L. Body mass index and mortality among nonsmoking older persons. JAMA 1988; 259: 1520–1524.
19. Jennings S, Carey D. Capacity and equity in cardiac rehabilitation in the eastern region: good and bad news. Ir J Med Sci 2004; 173: 151–154.
20. Friedewald WT, Levy RI, Fridrikson DS. Estimation of concentrations of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
21. Pashkow FJ, Dafoe WA. Clinical cardiac rehabilitation 2nd education. Baltimore: Williams and Wilkins; 1999. pp. 137–147, 458–466.
22. Brunzell JD. Hypertriglyceridemia. NEJM 2007; 357: 1009–1017.
23. Kojuri J, Vosoughi AR, Akrami M. Effects of anethum graveolens and garlic on lipid profile in hyperlipidemic patients. Lipids Health Dis 2007; 6: 5.
24. Yates BC, Heeren BM, Keller SM, Agrawal S, Stoner JA, Ott C. Comparing two methods of rehabilitation for risk factor modification after a cardiac event. Rehabil Nurs 2007; 32: 15–22.
25. Höfer S, Kullich W, Graninger U, Brandt D, Gassner A, Klicpera M, et al Cardiac rehabilitation in Austria: short term quality of life improvements in patients with heart disease. Wien Klin Wochenschr 2006; 118: 744–753.
26. Hatmi ZN, Tahvildari S, Ghafarzadeh Motlag A, Sabouri Kasnani A. Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC Cardiovasc Disord 2007; 7: 32.
27. Sarraf-Zadegan N, Sayed-Tabatabaei FA, Bashardoost N, Maleki A, Totonchi M, Habibi HR, et al The prevalence of coronary artery disease in an urban population in Isfahan, Iran. Acta Cardiol 1999; 54: 257–263.
28. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410–418.
29. Ades PA, Savage PD, Poehlman ET, Brochu M, Fragnoli-Munn K, Carhart RL Jr. Lipid lowering in the cardiac rehabilitation setting. J Cardiopulm Rehabil 1999; 19: 255–260.
30. Senuzun F, Fadiloglu C, Burke LE, Payzin S. Effects of home-based cardiac exercise program on the exercise tolerance, serum lipid values and self-efficacy of coronary patients. Eur J Cardiovasc Prev Rehabil 2006; 13: 640–645.
31. Mendis S, Abegunde D, Yusuf S, Ebrahim S, Shaper G, Ghannem H, Shengelia B. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ 2005; 83: 820–829.
32. EUROASPIRE Study Group (Wood DA for the). EUROASPIRE–A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18: 1569–1582.
33. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998; 158: 1238–1244.
34. Sueta CA, Chowdhury M, Boccuzzi SJ, Smith SC Jr, Alexander CM, Londhe A, et al Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83: 1303–1307.
35. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II group. Lancet 2001; 357: 995–1001.
36. LaBresh KA, Ellrodt AG, Gliklich R, Liljestrand J, Peto R. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med 2004; 164: 203–209.